Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 18/20 | 0.79 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.79 |
| ▸ | IL6 | P05231 | 9/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24247632 | 0.90 | TLR7 (0.82) | TLR7IL6 | |
| SCHEMBL4124603 | 0.89 | TLR7 (0.84) | TLR7NUDT1IL6 | |
| SCHEMBL1641626 | 0.89 | TLR7 (1.00) | TLR7NUDT1IL6 | |
| SCHEMBL29381054 | 0.89 | TLR7 (1.00) | TLR7NUDT1IL6 | |
| SCHEMBL1146492 | 0.89 | TLR7 (0.77) | TLR7NUDT1IL6 | |
| SCHEMBL19369897 | 0.87 | TLR7 (0.75) | TLR7NUDT1IL6 | |
| SCHEMBL1146409 | 0.86 | TLR7 (0.81) | TLR7NUDT1IL6 | |
| SCHEMBL1146215 | 0.86 | TLR7 (0.76) | TLR7NUDT1IL6 | |
| SCHEMBL1146185 | 0.86 | TLR7 (0.79) | TLR7NUDT1IL6 | |
| SCHEMBL1146727 | 0.86 | TLR7 (0.79) | TLR7NUDT1IL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108348618-B | Adenine conjugate compounds and their use as vaccine adjuvants | 大日本住友制药株式会社 | 2021-06-15 | — | — | CN | disclosed |
| EP-3355933-B1 | ADENINE CONJUGATE COMPOUNDS AND THEIR USE AS VACCINE ADJUVANTS | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2020-05-06 | — | — | EP | disclosed |
| US-10597397-B2 | Adenine conjugate compounds and their use as vaccine adjuvants | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-03-24 | — | — | US | disclosed |
| US-20180282334-A1 | ADENINE CONJUGATE COMPOUNDS AND THEIR USE AS VACCINE ADJUVANTS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-10-04 | — | — | US | disclosed |
| EP-3355933-A1 | ADENINE CONJUGATE COMPOUNDS AND THEIR USE AS VACCINE ADJUVANTS | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2018-08-08 | — | — | EP | disclosed |
| US-20090105212-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2009-04-23 | — | — | US | disclosed |
| US-20090105212-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2009-04-23 | — | — | US | disclosed |
| US-20090105212-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1939201-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10597397-B2 | Adenine conjugate compounds and their use as vaccine adjuvants | ADORA1, ADORA2A, ADORA3 | TLR7 12/4885NUDT1 92/4885IL6 2547/4885 |
| US-20180282334-A1 | ADENINE CONJUGATE COMPOUNDS AND THEIR USE AS VACCINE ADJUVANTS | ADORA1, ADORA2A, ADORA3 | TLR7 12/4885NUDT1 92/4885IL6 2547/4885 |
| US-20090105212-A1 | NOVEL ADENINE COMPOUND | XDH, ADORA1, NUDT1 | TLR7 396/4885NUDT1 3/4885IL6 3519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.